All In Biotech

NDA 020145 · Uspharma

Nitro-Dur

Nitroglycerin · Transdermal · Nitrate Vasodilator

Last checked: Nov 19, 2026Latest source record: Jan 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Dec 10, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

237

47 Phase 3, 10 recruiting

FAERS reports

41,486

33,732 serious, 5,555 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

You must consult your doctor for important information before using this drug.

What it is approved for

From the label in effect May 30, 2023.

INDICATIONS AND USAGE Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 10, 1985 Original approval
6 products under this application
  • NITRO-DUR · NITROGLYCERIN 0.6MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NITRO-DUR · NITROGLYCERIN 0.3MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NITRO-DUR · NITROGLYCERIN 0.1MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NITRO-DUR · NITROGLYCERIN 0.8MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NITRO-DUR · NITROGLYCERIN 0.4MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NITRO-DUR · NITROGLYCERIN 0.2MG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitroglycerin" as an intervention, any sponsor and status, largest first.

All 237 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea3,552
  • pain3,187
  • fatigue2,860
  • myocardial infarction2,772
  • nausea2,731
  • fall2,498
  • chest pain2,475
  • dizziness2,447
  • drug ineffective2,420
  • headache2,254
  • diarrhoea2,182
  • hypotension2,061

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004987
20051,123
2006962
2007719
2008941
20091,246
20101,413
20112,285
20121,729
2013882
20142,472
20151,485
20161,677
20171,755
20182,122
20192,302
20202,119
20212,233
20222,874
20232,854
20242,810
20252,707
20261,785

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nitro-Dur (Nitroglycerin)

2024 spending

$2.7M

Beneficiaries

419

1,298 claims

Per beneficiary

$6,549

$50.83 per unit

View as table
YearSpending
2020$3,471,995
2021$3,953,896
2022$3,428,121
2023$3,463,632
2024$2,743,826

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,056 on PubMed

Sponsor: Uspharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.